AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for accelerated ... making it the most common form. By the end of the year, it is estimated that there ...

AstraZeneca PLC ... to withdraw their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of lung cancer.

However, AstraZeneca and its partner Daiichi Sankyo withdrew their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of ...

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan (Dato-DXd), to treat advanced ...

FDA approves AstraZeneca’s Imfinzi for limited-stage ... SCLC is a highly aggressive form of lung cancer. The FDA approval was based on results from the ADRIATIC Phase 3 trial, presented during ...

and its partner Daiichi Sankyo have decided to withdraw their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of lung ...

AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the ... on this site does not imply any form of partnership, agency, or endorsement.

LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision ...